Abbott Atrial Fibrillation Post Approval Study

Inclusion Criteria:

1. Subject must provide written informed consent prior to any clinicalinvestigation-related procedure.

2. Documented symptomatic persistent AF, which is defined as continuous AF sustainedbeyond 7 days and less than 1 year that is documented by a physician's note AND oneof the following:

3. a 24-hour Holter within 180 days prior to consent/enrollment, showingcontinuous AF OR

4. two electrocardiograms (from any form of rhythm monitoring) showing continuousAF: i. that are taken at least 7 days apart but less than 12 months apart. ii. Ifelectrocardiograms are more than 12 months apart, there must be one or more SRrecordings in between or within 12 months prior to consent/enrollment NOTE: The mostrecent ECG must be within 180 days of consent/enrollment. Documented evidence of theAF episode must either be continuous AF on a 12-lead ECG or include at least 30seconds of AF from another ECG device.

5. Subject must have failed, intolerance, or contraindication to a Class I-IV AADmedication.

6. Able and willing to comply with all pre-, post-, and follow-up testing andrequirements

Exclusion Criteria:

1. Previously diagnosed continuous AF >12 months (longstanding persistent AF)

2. Previous left atrial surgical or catheter ablation for atrial fibrillation or aprevious procedure that required an incision in the left atrium with resulting scar

3. Documented or known intracardiac thrombus on imaging

4. History of atriotomy or ventriculotomy within 4 weeks prior to the initial procedure

5. Patients with prosthetic valves

6. Diagnosed atrial myxoma

7. Acute illness or active systemic infection or sepsis

8. Patient is unlikely to survive the protocol follow up period of 36 months

9. Presence of other medical, social, or psychological conditions that, in theinvestigator's opinion, could limit the subject's ability to participate in theclinical investigation or to comply with follow-up requirements, or impact thescientific soundness of the clinical investigation results

10. Enrollment in an investigational study evaluating another device, biologic, or drugthat may interfere with this clinical investigation at the time of the initialprocedure or within 30 days prior to the initial procedure

11. Investigator deems at the time of screening for inclusion in the study that thepatient's treatment plan does not or likely will not include use of the studycatheter